Funding
This work was supported in part by the National Institutes of Health. This work was supported in part by the MD Anderson Cancer Center Support Grant from the National Cancer Institute of the National Institutes of Health (NIH/NCI P30 CA016672, CA217685) and the T32 training grant CA101642. L.A.M. is supported by a NIH-NCIK07-CA201013 grant. S.H.G. is supported by CPRIT RP160674 and Komen SAC150061. K.M.P. is supported by CPRIT RP 170259.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
DISCLOSURE
L.A.M. reports consulting fees from Bristol Meyers Squibb, advisory board participation for GlaxoSmithKline, and stocks in Crisper, Invitae, and Bristol-Myers Squibb. C.C.S. reports partial research funding from AstraZeneca and stock in Inform Genomics. The remaining authors report no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Huepenbecker, S.P., Fu, S., Sun, C.C. et al. ASO Visual Abstract: Medicaid Expansion and Postoperative Mortality in Women with Gynecologic Cancer—A Difference-in-Difference Analysis. Ann Surg Oncol 30, 1520–1521 (2023). https://doi.org/10.1245/s10434-022-12709-4
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-022-12709-4